Caris Life Sciences to Present Innovative Research at ESMO 2024
Caris Life Sciences (Caris), in partnership with prominent cancer centers, is preparing to unveil significant research findings that highlight the clinical benefits of comprehensive molecular profiling at the European Society for Medical Oncology (ESMO) Congress 2024. The research will cover seven studies that encompass a variety of tumor types, demonstrating Caris' contribution to the field of precision medicine.
Valuable Insights Across Various Cancer Types
During ESMO 2024, Caris and its collaborators from the biopharma sector and respected cancer centers will share their findings at Booth #608. These results emphasize the remarkable capabilities of Caris' extensive multi-modal database, which provides innovative insights into cancer that can significantly affect a patient's diagnosis, prognosis, treatment plan, and responses to therapies.
Dedication to Precision Oncology
George W. Sledge, Jr., MD, Caris' Executive Vice President and Chief Medical Officer, remarked that the research presented at the ESMO Congress reflects Caris' commitment to data-driven molecular innovation. He highlighted how the growing collaborative network is addressing some of the most urgent questions in precision oncology today.
Groundbreaking Discoveries in Cancer Treatment
Sledge added, "The findings highlight the essential role of comprehensive profiling in cancer care and the promise of large clinico-genomic datasets. Our extensive sequencing and data analysis efforts are revealing new pathways for personalized therapies that could transform cancer treatment." Through these initiatives, Caris is leading the charge toward better patient outcomes and more tailored treatment options.
Noteworthy Presentations at ESMO 2024
This year, Caris will showcase significant findings through both mini oral presentations and poster sessions:
Mini Oral Presentations
- Metastatic hormone receptor-positive breast cancer outcomes: This study examined 628 patients with BRCA1, BRCA2, or PALB2 pathogenic variants to explore the intersection of genomics and targeted therapy sequencing. (Abstract Number: 342MO)
- Atlas of tertiary lymphoid structures in solid tumors: This research investigates genomic characteristics and their ability to predict responses to immunotherapy. (Abstract Number: 75MO)
Poster Presentations
- Impact of TLS Status: An analysis of patient outcomes with high tumor mutational burden (TMB) or microsatellite instability-high (MSI-H) status undergoing immune checkpoint inhibitors. (Abstract Number: 1051P)
- Comparison of HER2 Immunohistochemistry Scoring: This presentation evaluates the scoring criteria used in assessing endometrial endometrioid adenocarcinoma (EEA). (Abstract Number: 739P)
- Evaluating c-Met Protein Overexpression: The METPRO study investigates the prognostic significance of c-Met protein presence alongside concurrent biomarker evaluation. (Abstract Number: 1303P)
- HER2 Low-Expressing Tumors: The presentation will cover the genomic landscape and prognostic implications of HER2 low-expressing tumors. (Abstract Number: 126P)
- Prostate Cancer Insights: This study explores high PSMA/FOLH1 mRNA expression in prostate cancer and its clinical relevance. (Abstract Number: 1653P)
Caris Precision Oncology Alliance
The Caris Precision Oncology Alliance (POA) consists of 95 cancer centers, including 46 designated by the NCI. This partnership aims to advance precision oncology and promote biomarker-driven research to enhance patient outcomes.
Together, Caris and POA members are dedicated to establishing and refining molecular care standards that prioritize predictive and prognostic markers.
About Caris Life Sciences
Caris Life Sciences is a leading next-generation AI TechBio company at the forefront of precision medicine. The organization is committed to transforming healthcare through innovative solutions and comprehensive molecular profiling, which includes Whole Exome and Whole Transcriptome Sequencing. By leveraging advanced AI and machine learning algorithms on a vast array of data, Caris has developed powerful tools for early detection, diagnosis, treatment selection, and drug development.
Founded with the vision to fully harness the potential of precision medicine, Caris prioritizes the well-being of both its employees and patients from diverse backgrounds. Headquartered in Texas with offices around the globe, Caris collaborates internationally to deliver essential services that enhance healthcare outcomes in various populations.
Contact Information
For media inquiries, please reach out to:
Corporate Communications
Email: info@carislifesciences.com
Phone: 214.294.5606
Frequently Asked Questions
What is Caris Life Sciences best known for?
Caris Life Sciences is widely recognized for its innovative approach to precision medicine, utilizing cutting-edge technology to provide comprehensive molecular profiling for cancer treatment.
What key findings will Caris present at ESMO 2024?
At ESMO 2024, Caris will present findings from seven studies that emphasize the significance of their multi-modal database in enhancing cancer diagnosis and treatment strategies.
What is the Caris Precision Oncology Alliance?
The Caris POA is a collaborative network of cancer centers and academic institutions focused on advancing precision oncology research and ensuring optimal standards of care for cancer patients.
How does Caris contribute to cancer research?
Caris enhances cancer research by integrating comprehensive molecular profiling with extensive clinical data, aiding clinicians and researchers in discovering new biomarkers that can lead to improved treatment outcomes.
How can I learn more about Caris Life Sciences?
To learn more about Caris Life Sciences and their innovative solutions, you can visit their official website or reach out to their communications team for additional information.
